Use of Variants of Dihydrofolate Reductase in Gene Transfer to Produce Resistance to Methotrexate and Trimetrexate

Bertino, Joseph R.; Zhao, Shi Cheng; Mineishi, Shin; Ercikan-Abali, Emine A.; Banerjee, D.

doi:10.1159/000061989

Search citation statements

Order By: Relevance

Paper Sections

Select...

Drug Resistance Gene Transfer For Myeloprotection1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2008

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1, [73][74][75][76][77][78][79][80][81][82][83][84][85] Myeloprotection-based gene therapy strategies have led to many preclinical studies 81,84,[86][87][88][89][90][91][92][93][94][95][96][97] and a few clinical studies.…”

Section: Drug Resistance Gene Transfer For Myeloprotectionmentioning

confidence: 99%

Hematopoietic stem cell gene therapy with drug resistance genes: an update

2005

View full text Add to dashboard Cite

Transfer of drug resistance genes into hematopoietic stem cells (HSCs) has promise for the treatment of a variety of inherited, that is, X-linked severe combined immune deficiency, adenosine deaminase deficiency, thalassemia, and acquired disorders, that is, breast cancer, lymphomas, brain tumors, and testicular cancer. Drug resistance genes are transferred into HSCs either for providing myeloprotection against chemotherapy-induced myelosuppression or for selecting HSCs that are concomitantly transduced with another gene for correction of an inherited disorder. In this review, we describe ongoing experimental approaches, observations from clinical trials, and safety concerns related to the drug resistance gene transfer.

show abstract